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Abstract
Hyperglycaemia in poorly controlled diabetic patients induces non-enzymatic glycosylation (glycation) of proteins, altering
their structure and physiological bioactivity. Alkaline phosphatase (ALP) is a membrane-bound exoenzyme which faces the
extracellular compartment. We have investigated the glycation of intestinal alkaline phosphatase in vitro and the consequences
of such molecular modifications on certain structural and functional characteristics. The effect of glycation on alkaline
phosphatase specific activity was determined after incubation of the enzyme with different sugars for various periods of time.
The formation of early reversible glycation products was determined by the measurement of fructosamine levels, while the
appearance of advanced glycation end products was estimated by spectrofluorometric analysis. A decrease in the specific
activity of ALP was associated both with an increase in fructosamine levels and with the appearance of AGE-characteristic
fluorescence. Changes in these parameters were found to depend on the incubation time, and on the concentration and glycating
capability of the sugar employed. Co-incubation with aminoguanidine slowed down the appearance of protein-linked
fluorescence, and additionally curbed the decrease in enzymatic specific activity. A significant correlation between the levels
of ALP-fructosamine and ALP-advanced glycation end product was observed. Patterns of protein bands fractionated by SDS-
PAGE were essentially identical for the nonglycated controls and the glycated samples. The electrophoretic mobility of the
band of alkaline phosphatase on cellulose acetate gels increased as a function of the incubation time and the glycosylating
power of the carbohydrate used. The present study provides evidence for the in vitro glycation of alkaline phosphatase, and
for the consecutive alteration of its activity and structure. (Mol Cell Biochem 181: 63–69, 1998)
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Introduction
One of the major consequences of hyperglycaemia in
poorly controlled diabetic patients is an excessive non-
enzymatic glycosylation (glycation) of proteins [1, 2]. This
process is initiated by a reducing sugar such as glucose,
which reacts with free amino groups of proteins resulting
in the formation of a Schiff base. A chemical rearrangement
then gives rise to the Amadori product, which is a ketoamine.
These reactions are reversible, increase with high sugar
levels and mainly occur on long-lived proteins. This reac-
tion reaches equilibrium in a period of weeks. With time,
Amadori products irreversibly progress to the formation of
crosslinked and fluorescent compounds. These compounds,
whose chemical structures have not been completely identi-
fied, are collectively known as advanced glycation end
products (AGEs). The AGEs continue to accumulate over
years, and are increased in processes such as diabetes and
normal aging [3, 4].
Non-enzymatic glycosylation has been demonstrated to
affect a number of proteins, including serum proteins such
as apoLDL [5], fibrin [6], albumin [7] and IGFBP-3 [8]; cell
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proteins (hemoglobin, superoxide dismutase) [9, 10]; and
extracellular matrix proteins such as collagen [11], myelin
[12] and laminin [13]. As a consequence of this glycation,
the structure and/or function of these proteins becomes
disturbed, altering their physiological bioactivity [14].
Alkaline phosphatase (ALP) is a membrane-bound metallo-
enzyme consisting of a group of isoenzymes: tissue non-
specific, intestinal, placental and germ-cell ALP [15]. The
protein is anchored to the cell membrane by a covalent linkage
with a glycosyl-phosphatidyl-inositol anchor [16]. In human
serum as well as in many other species, ALP predominantly
circulates as a hydrophilic homodimer. Although the physio-
logical role of this enzyme is still unknown, three functions
have been proposed for the human ALP in vitro: phos-
phohydrolysis of organic phosphomonoesters, phospho-
transferase activity and protein phosphatase activity. Skeletal
ALP has been implicated both in bone formation and mineral-
ization processes [17]. In intestine, as well as in kidney, ALP
has been proposed to regulate the transport of phosphate and
calcium [18, 19]. Thus, ALP appears to be implicated in
fundamental biochemical processes.
Since ALP is an exoenzyme which faces the extracellular
compartment, it is conceivable to suppose that its activity
and function could be especially affected by the environ-
mental sugar levels. To assess the rationale of this study, we
have investigated the glycation of intestinal alkaline phos-
phatase in vitro. The consequences of such molecular
modifications on certain structural and functional character-
istics of ALP have also been examined.
Materials and methods
Materials
Alkaline phosphatase from bovine intestine (ALP), α-
naphthyl phosphate, fast blue RR, sodium dodecyl sulfate
(SDS), acrylamide, coomassie brilliant blue R-250, p-
nitrophenyl phosphate (pNPP), aminoguanidine, and other
reactives of analytical degree were obtained from Sigma
Chemical Co., MO, USA. Test Combination Fructosamine
kit was kindly provided by Boehringer Mannheim Argentina.
In vitro glycation of ALP
Bovine intestinal ALP (10 mg/ml) was incubated in phosphate
buffered saline (PBS) containing penicillin (100 IU/ml),
streptomycin (100 µg/ml) and protease inhibitors, pH 7.4
at 37°C with or without 100 mM different sugars for the
periods indicated in the legends of the figures and tables [8].
The selected sugars were glucose (G), fructose (F) and
ribose (R) since they have different glycosylating capabili-
ties [20]. Thus, they will induce different rates and degrees
of glycation on proteins. In selected experiments, amino-
guanidine (250 mM) was included in the incubation mixture,
to examine the possible participation of AGEs in structural
and functional alterations which might appear in ALP as a
consequence of its glycation. In other experiments, glucose
was added to the incubation mixture at a concentration of
30 mM, to evaluate the dose-dependence of the modification
of ALP parameters. At the end of each incubation period,
the aliquots of ALP were concentrated and separated from
low molecular weight molecules by centrifugation/filtration
with Centricon 10 kDa cut-off filter cartridges (Amicon
Inc., Beverly, MA, USA).
Determination of glycated products
The formation of early glycation products on ALP was assayed
by the fructosamine method (Test combination fructosamine
Kit, kindly provided by Boehringer Argentina) [8]. The
presence of AGEs on ALP was assessed by their characteristic
fluorescence-emission maximum at 440 nm upon excitation
at 366 nm. For this assay, the protein concentration of all
samples was adjusted to 1 mg per milliliter, and fluorescence
measurements were expressed as percentage relative fluore-
scence compared to that of a 1 µg/ml quinine standard, as we
have previously described [21].
Measurement of alkaline phosphatase specific activity
Aliquots of either glycated or non-glycated ALP were
assayed incubating approximately 0.001 µg/ml ALP with
5 mM pNPP in 55 mM Glycine/0.55 mM MgCl
2
 buffer, pH
10.5 at 37°C for 20 min. The production of pNP was deter-
mined by optical density at 405 nm [21]. Protein con-
centration was determined by the Bradford method [22].
Separation of ALP isoforms by electrophoretic methods
To evaluate possible changes in the electrophoretic mobility
of ALP during its glycation, aliquots corresponding to 1 µg
protein were electrophoresed on gelatinized cellulose
acetate (Cellogel, Chemetron Milano, Italy), at a constant
current of 1 mA/cm, during 50 min. The enzymatic reaction
was then performed by placing the gel on an agar phase
containing α-naphthyl phosphate as substrate, at 37°C for
30 min. The product formed on the cellulose acetate gel, α-
naphthol, was then allowed to react with Fast Blue RR (also
in an agar phase) for 20 min at 25°C. The coloured ALP
bands were finally evaluated by densitometric analysis and
Rf determination [23].
65
To test for changes in the molecular weight patterns of
ALP during glycation, this protein was also separated by
polyacrylamide gel electrophoresis (PAGE) in the presence
of SDS using a Laemmli Tris-glycine buffer, pH 8.6 [24].
Aliquots of ALP with different degrees of glycation were
boiled for 3 min before loading on a 12.5% acrylamide gel.
After electrophoresis, the gels were fixed and stained with
0.1% Coomassie brillant blue R-250. Prestained molecular
weight markers were run in a parallel lane.
Statistical methods
At least 3 experiments were performed for each experi-
mental condition. Data are expressed as the mean ± S.E.M.
Statistical differences were analysed using Student’s t-test or
analysis of variance when suitable. Linear correlation analysis
was performed by Pearson’s correlation coefficient.
Results
The effect of glycation on alkaline phosphatase specific
activity was determined after incubation of the enzyme with
100 mM of different sugars. As shown in Fig. 1, the decrease
in ALP activity depends both on the length of the incubation
period and on the relative glycating power of the sugar
employed. Small changes in the ALP activity of the control
sample were observed during the course of these experi-
ments (45.3 ± 0.7 vs. 39.2 ± 0.9 nmol pNP/min.µg protein;
for 1 vs. 35 days).
In order to evaluate the formation of early reversible
glycation products, we determined the concentration of
fructosamine in all the ALP samples. Figure 2 shows that
the increase in fructosamine was dependent both on the time
of the incubation and on the glycosylating capacity of each
sugar. This increment in every case reached a maximum after
14 days of incubation. No significant differences were
found in the degree of glycation in the control samples (31
± 4 and 26 ± 5 µmol fructosamine/g protein for 1 and 35
days, respectively).
The extent of advanced glycation end product formation
on ALP was evaluated by measuring specific fluorescence.
After 1 week incubation, fluorescence characteristic of AGEs
was detected in ALP samples incubated in the presence of
different sugars (Fig. 3). The fluorescence-excitation
spectrum of each sample showed a maximum at 440 nm. The
excitation intensity at 440 nm increased when ALP was
incubated with fructose and ribose. On the other hand, after
7 days incubation the spectra of both the control sample and
glucose were found to be closely similar. Table 1 shows the
percentage relative fluorescence/mg protein in ALP samples
incubated with different sugars at a concentration of 100 mM
Fig 1. Time-dependent effect of non-enzymatic glycosylation on ALP
activity. ALP was incubated in PBS alone (● ), or PBS with 100 mM glucose
(n), fructose (▲) or ribose (▼) at 37°C for different periods of time. Aliquots
were removed at the indicated times and ALP activity was assayed. Data
are expressed as a percentage of basal activity, mean ± S.E.M. n = 6.
Fig. 2. Time-dependent effect of non-enzymatic glycosylation on fructo-
samine levels. ALP was incubated in PBS alone (● ), or PBS with 100 mM
glucose (n), fructose (▲) or ribose (▼) at 37°C for different periods of time.
Amadori products formed on ALP were assessed by the fructosamine levels.
Data are expressed as mean ± S.E.M. n = 6.
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2 weeks, submitted to centrifugation/filtration as described
in Materials and methods, and finally evaluated for enzy-
matic specific activity and protein-linked fluorescence.
Aminoguanidine, a compound which has been shown to
inhibit the formation of AGEs but not of Amadori products,
was found to reduce by 90% the AGE-associated fluor-
escence induced by 2 weeks incubation with ribose (Fig. 4).
In addition, the presence of aminoguanidine together with
ribose increased ALP specific activity to 72% of time-paired
control samples (compared to 33% when ALP was incubated
2 weeks with ribose alone). No significant differences were
found in these parameters between control samples in-
cubated with or without aminoguanidine (data not shown).
In further experiments, ALP was incubated with in-
creasing glucose concentrations (0, 30 and 100 mM) at 37°C
for 5 weeks. In this situation, a dose-dependence was found
both for ALP specific activity and for protein-linked fluor-
escence: as glucose levels rose, so did the inhibition of
enzymatic activity and the AGE-specific fluorescence per
mg protein (Table 2).
We next evaluated the possible structural changes in ALP
which could have occurred as a consequence of its glycation.
The patterns of protein bands fractionated by SDS-PAGE
were essentially identical for the nonglycated controls and
the glycated samples at all incubation times (data not shown).
Additionally, samples were electrophoresed on cellulose
acetate gels. The bands of ALP activity were visualized by
an in situ colorimetric reaction as described in Materials
Fig. 3. Fluorescence-emission spectra of control ALP (● ) and ALP
incubated with 100 mM glucose (n), fructose (▲) or ribose (▼) at 37°C for 7
days. (λexc = 366 nm).
Table 1. Relative fluorescence per mg protein after incubation of ALP at
37°C with different sugars (100 mM) and for different periods of time
Relative fluorescence at 440 nm (%)*
Time [days] Control Glucose Fructose Ribose
7 13.6 13.6 19.3 29.3
14 11.6 18.4 29.5 142.5
35 12.2 22.3 30.8 157.5
*expressed as percent fluorescence relative to a quinine standard sample.
for several incubation periods. Glucose, the weaker glycating
agent, only induced AGE accumulation on ALP as from 14
days of incubation. AGE-ALP increased as a function both of
the time of incubation and the potency of the glycating sugar,
ribose being the strongest of all sugars tested.
Thus, the decrease in the specific activity of ALP samples
incubated for different periods was associated both with an
increase in fructosamine levels and with the appearance of
AGE-characteristic fluorescence. A significant correlation
between the levels of fructosamine-ALP and AGE-ALP was
observed after 7 (p < 0.02), 14 (p < 0.05) and 35 (p < 0.01)
days of incubation.
In an attempt to examine the participation of covalently-
bound AGEs in the structural and functional alterations of
ALP, 250 mM aminoguanidine was added both to a control
ALP sample (no sugar added), and to a sample containing
ALP and 100 mM ribose. These samples were incubated for
Fig. 4. Effect of the co-incubation of aminoguanidine on ALP specific
activity and relative fluorescence at 440 nm. ALP was incubated at 37°C for
2 weeks in PBS alone (C), PBS with 100 mM ribose (R) or PBS with 100 mM
ribose and 250 mM aminoguanidine (R+AG). ALP specific activity is
expressed as percentage of basal activity, mean ± S.E.M. n = 6, and relative
fluorescence is given per mg protein, as described in Materials and methods.
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Table 2. Alkaline phosphatase specific activity and relative fluorescence
at 440 nm of ALP samples incubated with different concentrations of glucose
at 37°C for 5 weeks as described in Materials and methods
Glucose [mM] ALP [% Basal] Relative Fluorescence (%)
0 100 ± 1 13
30 54 ± 0.5 19
100 33 ± 1 22
Fig. 5. ALP was incubated in absence of carbohydrate (C) or in the presence
of 100 mM glucose (G), fructose (F) or ribose (R) at 37°C for 14 days and
submitted to electrophoresis on gelatinized cellulose acetate as described
in Material and methods. Arrow indicates the origin.
and methods. Figure 5 shows the glycated and non-glycated
ALP bands after 14 days incubation with 100 mM of each
sugar. A decrease in the intensity of the band, and an increase
in its mobility, can be seen in the samples incubated with
fructose and ribose. The area under each peak was integrated
to estimate ALP specific activity. These values, expressed
as percentage of control, were generally found to be similar
to those obtained with the ALP assay using pNPP as a
substrate (Table 3). This correlation decreased when ALP
specific activity was lower than 30% of incubation-time
paired control samples. The Rf was determined for the peak
of activity in each case. As shown in Table 3, the electro-
phoretic mobility of the band of ALP activity for each sugar
increased as a function of the incubation time. On the other
hand, the increase in the Rf for each incubation time was
observed to depend on the glycosylating power of the
carbohydrate used. The order of potency was G < F < R, in
agreement with their effects on the inhibition of ALP activity,
on ALP fructosamine levels and on AGE formation in the
samples. After 5 weeks incubation with different sugars, a
significant linear correlation was found between the changes
in the ALP mobility as assessed by the changes in the Rf and
either the ALP-fructosamine levels (r2: 0.992, p < 0.01), or
AGE-ALP formation (r2: 0.983, p < 0.02).
Table 3. Increment in the electrophoretic mobility of ALP incubated at
37°C with different sugars (100 mM) and for different periods of time
∆Rf (%)*
Time [days] Control Glucose Fructose Ribose
1 0 0 0 0
7 0 0 0 9 (58)
14 0 0 6 (57) 35 (22)
35 0 12 (58) 24 (10) 76 (4)
*expressed as percent changes in the Rf of glycated ALP bands, compared
to the corresponding (incubation-time paired) control sample. Values given
between brackets when ∆Rf > 0 correspond to the intensity of the ALP
band measured by densitometric analysis and expressed as percentage of
incubation-time paired control samples. No significant differences were
found in this parameter between control samples and samples with ∆Rf = 0.
Discussion
The non-enzymatic glycosylation of different proteins has
been extensively documented with in vitro as well as in
vivo studies, in animal models and human diabetes [1, 2,
14]. This molecular modification, which includes early,
intermediate and advanced glycosylation products, alters
both the structural and functional properties of proteins.
Consequently, it has been suggested that such alterations
could be involved in the pathophysiology of diabetic
complications. In this study, we have examined the non-
enzymatic glycosylation of intestinal alkaline phosphatase.
We have chosen this iso-enzyme as a model ALP, and
studied its possible in vitro glycation together with the
consequences of such a modification on certain structural
and functional properties.
The measurement of ALP fructosamine levels was used
to monitor the accumulation of early (Amadori) glycation
products, while the formation of AGEs was estimated by
means of spectrofluorometric analysis. The in vitro gly-
cation of ALP was found to proceed as a function of the
incubation time and of the glycating capability of the sugar
employed (Fig. 2, Table 1). A positive correlation was also
found between alkaline phosphatase AGE and fructosamine
levels. This is consistent with previous studies which have
shown AGE formation to be a direct function of the Amadori
product concentration at equilibrium [25, 26].
A gradual inactivation of ALP specific activity occurred
during incubation of the enzyme with all the monosaccharides
tested (Fig. 1). In general, this inhibition of ALP was
inversely associated both with fructosamine levels and AGE-
specific fluorescence. However, after short incubation
periods (e.g. 24 h), visible increases in the levels of Amadori
products were found on ALP, without there being any
significant changes in its enzymatic activity. On the other
hand, co-incubation for longer periods (e.g. 2 weeks) with
aminoguanidine, an inhibitor of the formation of AGEs but
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not of early glycation products, was found to diminish the
appearance of ALP-linked fluorescence, and accordingly
also curbed the decrease in ALP specific activity (Fig. 4).
These observations suggest that the amino groups initially
compromised in the glycation process are not involved in,
or are not close to, the ALP active site. As the incubation
proceeds, the observed decrease in ALP activity could be
due to one or more different causes: direct glycation of
sterically less accessible free amino groups in close
proximity to the active site; covalent formation of inter- or
intramolecular crosslinks due to AGE moieties which,
through conformational changes in ALP, could either limit
the access of substrates to the enzymes’ active site, or
could prevent correct interaction between ALP monomers.
Nevertheless, as no differences were found in the molecular
weight patterns of samples (when submitted to SDS-PAGE),
formation of inter-molecular crosslinks must be discarded.
In several studies, sugars other than glucose have been
used to accelerate the in vitro glycation of proteins, which
in vivo occurs over a period of months or years [14]. In our
experiments, the observed ALP time-dependent inactivation
was found to be a direct function of the glycating capability
of the monosaccharide employed. Moreover, the order of
this relative glycating power was in agreement with previous
reports [14] (Ribose>Fructose>Glucose).
In diabetic patients, plasma glucose levels of 100 mM are
very rare: they can only appear briefly during the acute
hyperglycaemic crises of NIDDM [34]. However, in poorly
compensated diabetic individuals it is not infrequent to find
plasma glucose concentrations in the 20–30 mM range. In
this context, we studied the effect of 30 mM glucose on
certain alkaline phosphatase parameters: in this case, after
an incubation of 5 weeks, we found an inhibition of ALP
specific activity, and the appearance of AGE-specific
protein-linked fluorescence (Table 2). Although significant,
the modification of these parameters was 69 and 67%,
respectively, of those found after a 5 week incubation with
100 mM glucose. These results are consistent with a glucose
dose-dependence, both for the inhibition of enzymatic
activity, and for the appearance of ALP-linked AGEs.
In various studies, changes have been demonstrated in the
structural properties of enzymes and other proteins as a
consequence of their glycation [1, 2]. In most of these cases,
free ε-amino groups of Lys residues are the main sites for
glycation. If this were the case with ALP, the non-enzymatic
glycosylation of Lys residues could produce a relative
increase in the proteins negative surface charge, which in
turn would lead to an increase in its electrophoretic mobility
in an alkaline environment. Present evidence lends support
to this suggestion: in our experiments, the electrophoretic
mobility of the ALP band increased in a time-dependent
manner (Fig. 6 and Table 2). The changes in Rf, used to
evaluate this effect, were found to correlate directly with
ALP fructosamine and AGE levels. However, these alter-
ations in the ALP bands electrophoretic properties could
also be at least partly accounted for by AGE-induced
conformational changes decreasing the molecules’ surface
area/volume ratio.
The precise molecular mechanism by which glycation
induces these effects remains unclear. Alkaline phosphatases
are a family of isoenzymes widely distributed in nature with
close amino acid homology of sequence [15]. The human
intestinal ALP sequence is well known, as is its active site.
The same ALP amino acid residues controlling catalysis
(Asp91, Ser92, Arg166), and those which determine binding of
the protein to Zn2+ and Mg2+, have been found from bacteria
to humans [27]. Human intestinal ALP shows 87% positional
identity with placental ALP, and 57% amino acid identity with
liver/bone/kidney ALP [28]. Intestinal ALP includes 17
lysine residues [28], which are possible candidates for non-
enzymatic glycosylation. It is thus likely that the reducing
sugar binds to lysine residues close to or involving the active
site of the enzyme.
The precise contribution of the in vivo glycation of
intestinal ALP, if it does occur, to physiological variations
in its enzymatic activity remains to be determined. Intestinal
ALP activity has been found to depend on genetic, hormonal
and dietary factors. In either starch- or sucrose-fed obese
spontaneous hypertensive/NIH corpulent rats, which
exhibit some of the metabolic and pathological alterations
associated with NIDDM, tissue intestinal ALP activity was
found to be depressed when compared with starch-fed (but
not sucrose-fed) lean control rats [29]. On the other hand,
in alloxan insulin-deficient diabetic rats fed ad libitum,
tissue intestinal ALP activity was increased compared with
control rats. However, this was not the case when alloxan
diabetic rats were fed a restricted diet, suggesting that
increased activity of tissue intestinal ALP is only a secondary
effect of insulin deficiency, caused by the increased food
intake resulting from insulin deficiency [30]. Moreover, in
streptozotocin-induced insulin defficient rats, circulating
(serum) intestinal ALP activity was found to be markedly
elevated when compared with control rats [31, 32]. Never-
theless, it should be noted that no physiological role has been
found for serum ALP: the biologically active enzyme is
normally anchored to tissue membranes, and is thus exposed
to the extracellular medium. In this context, it is conceivable
that ALP, together with other extracellular matrix proteins,
could become excessively glycated in diabetic individuals
in vivo [33]. Thus, it would be possible to hypothesize that
membrane-bound ALP, with reduced bioactivity due to
excessive glycation, could coexist with the increased serum
ALP activity found in insulin-defficient individuals.
The present study provides evidence for the in vitro
glycation of alkaline phosphatase, and for the consecutive
alteration of its activity and structure. Further studies are
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required to determine whether ALP becomes glycated in
diabetic individuals, and, if so, what would be the functional
consequences of these modifications in vivo.
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